Dense Area
Background
In the field of human genetics, a "dense area" typically refers to a region of the genome characterized by a high concentration of genetic markers, such as Single Nucleotide Polymorphisms (SNPs), or a genomic region exhibiting strong linkage disequilibrium (LD). Modern genomic research, particularly Genome-Wide Association Studies (GWAS), relies on genotyping a vast number of SNPs across the genome to identify genetic variants associated with specific traits or diseases. [1] Early GWAS utilized less dense SNP arrays, and subsequent research emphasized the need for "better coverage" afforded by "newer, more dense SNP arrays" to improve the ability to detect associations. [1] The concept also extends to "dense maps" used for estimating identity by descent and probabilistically inferring missing genotypes. [2]
Biological Basis
The biological significance of dense areas lies in their capacity to capture a more complete picture of genetic variation within a population. Regions with high SNP density allow researchers to more precisely pinpoint genetic loci associated with traits, even when the causative variant itself is not directly genotyped. This is often facilitated by linkage disequilibrium, where SNPs in close proximity on a chromosome are inherited together more often than expected by chance. Studies often define "gene regions on the basis of the LD pattern around the previously reported SNP" [3] and "many of the SNPs evaluated tended to group into easily recognizable linkage blocks". [4] Furthermore, "imputation analyses" leverage dense reference panels to infer genotypes for ungenotyped SNPs, effectively creating a "dense" dataset even from sparser genotyping arrays . [5], [6] This approach allows for a more thorough exploration of genetic variation and its impact on biological function, including metabolism, inflammation, and cardiovascular diseases. [7]
Clinical Relevance
The identification and characterization of dense areas are clinically relevant for understanding the genetic architecture of complex diseases. By providing "better coverage" of gene regions, dense SNP arrays and imputation strategies enhance the power of GWAS to discover "novel genetic variants" and "candidate genes" influencing health-related traits . [1], [3] For instance, such studies have identified loci associated with uric acid concentration and risk of gout [6] various metabolic traits [3] biomarkers of cardiovascular disease [8] persistent fetal hemoglobin [2] diabetes-related traits [9] C-reactive protein levels [4] subclinical atherosclerosis [1] and lipid concentrations. [5] A more comprehensive understanding of these genetic associations can contribute to improved risk prediction, diagnostic tools, and the development of targeted therapies.
Social Importance
The advancement in identifying and analyzing dense areas of genetic variation holds significant social importance. It underpins the progress in personalized medicine by enabling a more precise assessment of an individual's genetic predisposition to various conditions. By identifying genes and pathways involved in common diseases, this research contributes to public health strategies aimed at prevention and early intervention. The "full disclosure of the totality of our results, including all 'non-significant' associations" in large-scale studies further promotes scientific transparency and collaboration, accelerating the overall understanding of human health and disease susceptibility. [1] This continuous effort to map and understand genetic variations in dense regions is crucial for unraveling the complexities of human biology and improving global health outcomes.
Methodological and Statistical Constraints
The genomic coverage in these studies, often utilizing 100K or 300K SNP arrays, represents a subset of all known SNPs, which may lead to missing actual genetic associations or hinder comprehensive study of candidate genes. [10] This partial coverage also contributes to challenges in replicating previously reported findings, as different arrays may not sufficiently capture the same genetic variation. [11] Furthermore, the power to detect modest genetic effects is inherently limited by sample sizes and the extensive multiple testing required in genome-wide association studies, increasing the possibility of false-positive results despite statistical support or biological plausibility. [11] The practice of sex-pooled analyses, while mitigating multiple testing problems, may obscure SNPs associated with phenotypes exclusively in one sex, leaving such associations undetected. [10] Lastly, while imputation improves genomic coverage, it introduces a degree of estimation error, and differences in study design and power can lead to non-replication at the SNP level, even when associations are observed within the same gene region. [3]
Phenotypic Assessment and Population Generalizability
Phenotype characterization, particularly when involving the averaging of traits over extended periods, presents inherent challenges. For instance, combining echocardiographic measurements spanning two decades, taken with different equipment, could introduce misclassification and dilute the true genetic signal. [11] Such averaging also implicitly assumes that the same genetic and environmental factors influence traits uniformly across a wide age range, an assumption that may mask age-dependent genetic effects. [11] A significant limitation across many of these studies is their primary focus on populations of European descent, such as white individuals in the Framingham Heart Study or specific European ancestry cohorts. [11] This demographic specificity means that the generalizability of the findings to other ethnic groups and diverse ancestries remains largely unexplored, potentially limiting the broader applicability of the results.
Unexplored Gene–Environment Interactions and Remaining Knowledge Gaps
Genetic variants do not always act in isolation but can be profoundly influenced by environmental contexts. For example, associations of genes like ACE and AGTR2 with phenotypes may be modulated by factors such as dietary salt intake. [11] However, these studies generally did not undertake investigations of such gene-environment interactions, thus limiting a complete understanding of the complex interplay shaping phenotypic expression. [11] The identified genetic loci often explain only a fraction of the total phenotypic variation, indicating that much of the genetic architecture remains undiscovered. Identifying these additional sequence variants will require larger sample sizes and enhanced statistical power in future research. [12] The ongoing challenge of prioritizing and validating statistically significant associations, especially in the absence of immediate external replication, underscores the need for continued investigation to confirm true positive genetic signals and fully elucidate their biological roles. [13]
Variants
Genetic variations play a crucial role in influencing a wide range of biological processes, from cellular growth and differentiation to tissue structure and metabolism. These variations, particularly single nucleotide polymorphisms (SNPs), can impact gene activity, protein function, and ultimately contribute to complex traits such as tissue density. For instance, the region encompassing ZNF365 and LINC02929, where the variant rs10995190 is located, is significant for cellular regulation. ZNF365 (Zinc Finger Protein 365) is known to be involved in cell proliferation, apoptosis, and DNA repair, while LINC02929 is a long intergenic non-coding RNA that may modulate the expression of nearby genes. [1] Alterations in this regulatory axis by rs10995190 could affect the fundamental processes that govern tissue cellularity and organization, contributing to variations in tissue density. Similarly, the IGF1 gene, which encodes Insulin-like Growth Factor 1, is a key mediator of growth hormone effects, influencing cell growth, differentiation, and metabolism throughout the body. [14] The variant rs703556 near IGF1 or its associated LINC00485 could modify IGF1 signaling pathways, thereby affecting tissue development and overall cellular density. PRDM6 (PR/SET Domain Containing 6) is another gene with critical regulatory functions, acting as a histone methyltransferase that epigenetically controls gene expression, especially in vascular smooth muscle cell differentiation; the variant rs186749 in this gene could thus influence cellular development and structural integrity, impacting tissue density.
Other variants are associated with genes involved in cellular communication and tissue remodeling, which are central to establishing and maintaining tissue architecture. The region containing AREG (Amphiregulin) and BTC (Betacellulin) includes variants rs10034692 and rs12642133. Both AREG and BTC are ligands for the Epidermal Growth Factor Receptor (EGFR), a receptor tyrosine kinase that drives cell proliferation, differentiation, and survival, particularly in epithelial tissues like the mammary gland. [5] Variations in these genes can modulate EGFR signaling intensity, influencing cellular growth rates and tissue structure, which are direct determinants of tissue density. Furthermore, the CCDC170 - ESR1 locus, harboring the rs12665607 variant, is particularly relevant to hormone-sensitive tissues. ESR1 (Estrogen Receptor 1) is a primary mediator of estrogen's effects on cell proliferation, differentiation, and tissue homeostasis, with strong implications for breast tissue density and other hormone-responsive tissues. [12] CCDC170 (Coiled-Coil Domain Containing 170) has been linked to estrogen receptor activity and breast cancer risk. Therefore, rs12665607 could affect estrogen signaling pathways, leading to variations in tissue growth and density.
Finally, variants affecting genes related to cellular structure, metabolism, and immune responses can also contribute to the dense area phenotype. LSP1 (Lymphocyte-Specific Protein 1), with its associated variant rs3817198, is an actin-binding protein predominantly found in leukocytes, playing roles in cell motility and immune cell function . Alterations in immune responses or inflammatory processes, modulated by LSP1, can influence tissue remodeling and cellular infiltration, thereby affecting tissue density. The SSPN (Sarcospan) gene, along with the ITPR2-AS1 antisense RNA, and the variant rs11836164, are involved in maintaining cellular integrity and signaling, particularly in muscle tissue. Changes in these genes could impact cellular adhesion and the extracellular matrix, which are key components of tissue density. Moreover, the SGSM3, SGSM3-AS1, and ADSL genes, with the variant rs17001868, are related to cellular metabolism and signaling. ADSL (Adenylosuccinate Lyase) is an enzyme essential for purine biosynthesis. [13] Variations in these genes may subtly alter metabolic pathways or intracellular signaling, contributing to differences in cellular composition and overall tissue density. Lastly, TMEM184B (Transmembrane Protein 184B), an uncharacterized transmembrane protein, with its variant rs7289126, could be involved in cell surface interactions or transport, potentially impacting cell-to-cell communication and tissue organization.
Key Variants
| RS ID | Gene | Related Traits |
|---|---|---|
| rs10995190 | ZNF365 - LINC02929 | dense area measurement mammographic density measurement breast carcinoma estrogen-receptor negative breast cancer estrogen-receptor negative breast cancer, chronotype measurement |
| rs17001868 | SGSM3, SGSM3-AS1, ADSL | dense area measurement breast size |
| rs3817198 | LSP1 | dense area measurement breast carcinoma |
| rs703556 | IGF1 - LINC00485 | dense area measurement |
| rs10034692 | AREG - BTC | dense area measurement |
| rs12642133 | AREG - BTC | dense area measurement |
| rs12665607 | CCDC170 - ESR1 | dense area measurement |
| rs7289126 | TMEM184B | dense area measurement mammographic density percentage, mammographic density measurement |
| rs11836164 | SSPN, ITPR2-AS1 | dense area measurement |
| rs186749 | PRDM6 | dense area measurement mammographic density percentage, mammographic density measurement alopecia |
Definition and Measurement of Calcified Lesions
In the context of cardiovascular imaging, a "dense area" is precisely defined as a calcified lesion. Such a lesion is identified as an area comprising at least three connected pixels with a computed tomography (CT) attenuation greater than 130 Hounsfield Units (HU), based on 3D connectivity criteria. [1] This operational definition is applied to identify both coronary artery calcification (CAC) and abdominal aortic calcification (AAC), serving as a crucial diagnostic criterion for subclinical atherosclerosis. [1] The presence and extent of these dense areas are vital indicators of arterial health and risk for cardiovascular disease.
Measurement approaches involve quantitative scoring to assess the severity of these calcified lesions. A score for CAC and AAC is calculated by multiplying the area of the identified calcified lesion by a weighted CT attenuation score. [1] This weighting is dependent on the maximal CT attenuation (Hounsfield Units) observed within the lesion. [1] This methodology represents a modification of the established Agatston Score, adapted for use with multidetector CT (MDCT) scan protocols, ensuring consistent and reproducible measurements of atherosclerotic burden. [1]
Classification and Scoring of Atherosclerotic Burden
The classification of calcified lesions, such as CAC and AAC, primarily relies on a dimensional approach, quantifying the extent and density of calcification rather than a simple categorical presence or absence. The calculated scores, derived from the area and weighted CT attenuation, provide a continuous or semi-continuous scale to grade the severity of subclinical atherosclerosis. [1] This numerical assessment allows for a nuanced understanding of disease progression and risk stratification. For instance, studies have reported excellent intra- and inter-reader reproducibility for these CAC measurements, underscoring their reliability in clinical and research settings. [1]
While explicit severity gradations (e.g., mild, moderate, severe) are not detailed in the provided context, the quantitative nature of the scoring system inherently supports such classifications based on established thresholds in broader clinical practice. The use of these scores allows researchers to correlate genetic variants and environmental factors with the burden of atherosclerosis, contributing to a more comprehensive nosological system for cardiovascular health. [1] This objective measurement helps in identifying individuals at intermediate pre-test probability of cardiovascular disease who are more likely to develop clinical events. [11]
Clinical Terminology and Related Concepts
The key terms associated with "dense area" in this medical context are "coronary artery calcification" (CAC) and "abdominal aortic calcification" (AAC), which specifically denote the presence of calcified lesions in the coronary arteries and abdominal aorta, respectively. [1] These terms are integral to the nomenclature of subclinical atherosclerosis, which encompasses the early, asymptomatic stages of arterial disease. The measurements of CAC and AAC are considered subclinical atherosclerosis measures, distinct from overt clinical disease. [1]
Related concepts that complement the understanding of these dense areas include carotid artery intima-medial thickness (IMT) and endothelial dysfunction. [1] Endothelial dysfunction, often assessed via brachial artery flow-mediated dilation (FMD), is recognized as a fundamental component and a precursor of atherosclerosis. [11] Collectively, these traits—CAC, AAC, IMT, and FMD—serve as crucial intermediate phenotypes in the pathway from standard cardiovascular risk factors to the development of overt cardiovascular disease, providing valuable targets for genetic and epidemiological studies. [11]
Genomic Localization and Association Studies
The identification and characterization of a "dense area" within the genome, particularly in relation to various traits, primarily relies on advanced genomic methodologies such as Genome-Wide Association Studies (GWAS) and dense SNP arrays. These studies systematically survey the genome to pinpoint specific genetic loci, including single nucleotide polymorphisms (SNPs), that show significant statistical association with particular phenotypes or biomarker levels. [1] The use of more dense SNP arrays provides better coverage of gene regions, increasing the likelihood of identifying true genetic associations by capturing a wider range of variants within introns or exons, or within 60 kb of a candidate gene. [1] Statistical metrics like LOD scores and p-values are critical for determining the significance of these associations, with thresholds such as p < 5 × 10−7 often used to detect variants responsible for a notable percentage of trait variance, and replication studies serving as the absolute test of association. [13]
Further refinement in identifying these genomic regions involves imputation-based analyses, which can estimate genotypes for non-genotyped SNPs based on nearby markers, thereby maximizing genomic coverage and potentially uncovering additional associated SNPs or strengthening evidence for known loci. [2] This approach can also identify genomic boundaries for findings and evaluate whether multiple SNPs within a region represent distinct associations, offering a detailed understanding of the extent and relation of signals to local linkage disequilibrium. [3] Such genetic mapping provides crucial insights into potential biological pathways for further investigation, even for associations that may be challenging to replicate initially. [3]
Biomarker Profiling and Quantitative Trait Loci
Diagnostic approaches to characterize a dense area often involve comprehensive biomarker profiling to identify quantitative trait loci (pQTLs) that influence the levels of various circulating biological molecules. These include a wide array of blood and urine tests measuring inflammatory markers like C-reactive protein, osteoprotegerin, CD40 Ligand, myeloperoxidase, tumor necrosis factor alpha, and intercellular adhesion molecule-1. [13] Metabolic markers such as gamma-glutamyl transferase, B-type natriuretic peptide, alkaline phosphatase, serum urate, glycated hemoglobin, insulin, glucose, total cholesterol, HDL, triglycerides, and creatinine clearance are also routinely assessed. [13] These biochemical assays are typically performed after overnight fasting, using standardized methods like immunoenzymometric assays for C-reactive protein or enzymatic methods for lipids, providing precise quantitative data on biomarker concentrations. [3]
The clinical utility of biomarker profiling, particularly when combined with genetic data, lies in its ability to identify genetic variants that contribute to the variability of these traits in populations. [13] For instance, specific SNPs have been associated with average C-reactive protein levels, serum CD40 Ligand, myeloperoxidase, and urinary isoprostanes/creatinine, among others. [13] These findings help to connect specific genomic dense areas to their functional impact on physiological processes, providing insights into the genetic underpinnings of complex traits and potential risk factors for conditions like subclinical atherosclerosis. [1]
Population-Based Genetic Epidemiology
The diagnosis and understanding of "dense areas" are significantly advanced through large-scale, population-based genetic epidemiology studies. Cohorts such as the Framingham Heart Study, the ARIC Study, the Women's Genome Health Study, the Malmö Diet and Cancer Study, the Northern Finnish Birth Cohort of 1966, and the BRIGHT Study provide extensive demographic and clinical data on thousands of participants. [13] These studies typically involve recruiting diverse participants, often across various age ranges and ancestries, and conducting baseline and follow-up examinations to collect a broad spectrum of phenotype data and biological samples. [6]
The strength of these studies lies in their well-characterized community-based samples and the reproducible manner in which phenotypes, including subclinical atherosclerosis measures via high-resolution imaging, are collected. [1] The rigorous design of these cohorts, including protocols approved by ethical committees and standardized trait measurements, allows for robust genome-wide association analyses. [3] Such studies are crucial for identifying novel genetic variants and confirming previously reported candidate gene associations, contributing substantial information to the literature on the presence and strength of genetic influences on various traits. [1] They enable the detection of genetic loci that influence intermediate phenotypes on a continuous scale, offering more detailed insights into potentially affected biological pathways. [15]
Genetic Architecture and Regulatory Hotspots
"Dense areas" within the genome represent regions where multiple genetic variants or regulatory elements exert a concentrated influence on gene expression or protein function. Advanced genetic mapping technologies, such as dense SNP arrays and comprehensive haplotype maps, are crucial for thoroughly characterizing these regions by identifying numerous single nucleotide polymorphisms (SNPs) and their linkage disequilibrium patterns. [1] These studies reveal how specific genetic variations within such areas, including those affecting gene expression and protein levels (pQTLs), contribute to diverse biological traits. [16] For instance, the gene GALNT2, involved in O-linked glycosylation, highlights how enzymatic modifications in these regions can regulate protein function and influence broader biological processes. [12]
Metabolic Pathways and Homeostatic Regulation
"Dense areas" of metabolic activity are reflected by the intricate networks of endogenous metabolites that define an individual's physiological state. Metabolomics, by comprehensively measuring these intermediate phenotypes, offers insights into how genetic variations disrupt or fine-tune metabolic homeostasis. [15] For example, the efficiency of the fatty acid delta-5 desaturase reaction, a critical enzymatic step in lipid metabolism, is directly influenced by genetic modifications, leading to altered concentrations of polyunsaturated fatty acids like arachidonic acid. [15] Genes such as GCKR and those within the APOA cluster are integral to these processes, with their genetic variants impacting the complex balance of lipids, carbohydrates, and amino acids, thus revealing "dense areas" of metabolic regulation. [15]
Lipid Metabolism and Cardiovascular Health
"Dense areas" within the genome play a pivotal role in lipid metabolism, directly impacting cardiovascular health and disease susceptibility. Genetic variants in genes like FADS1 and LIPC, which encode key enzymes in long-chain fatty acid metabolism, significantly influence serum lipid profiles, including levels of high-density lipoprotein (HDL), low-density lipoprotein (LDL), and triglycerides. [15] Loci such as the APOA cluster and regions containing APOE and MLXIPL are strongly associated with these lipid traits, contributing to the polygenic nature of dyslipidemia and coronary heart disease risk. [17] The enzymatic activity, such as O-linked glycosylation mediated by GALNT2, further exemplifies how specific molecular processes within these "dense areas" can regulate proteins crucial for maintaining lipid homeostasis and preventing conditions like subclinical atherosclerosis. [12]
Cellular Signaling and Disease Pathogenesis
"Dense areas" of cellular signaling and regulatory networks underpin various pathophysiological processes, contributing to disease development and progression. For example, the immune response involves complex signaling pathways, where stimulation of the high-affinity IgE receptor on mast cells can lead to the production of allergy-promoting lymphokines and chemokines like Monocyte Chemoattractant Protein-1 (MCP-1). [18] Genetic polymorphisms in genes such as CCL2, which encodes MCP-1, are associated with variations in serum MCP-1 levels and influence the risk of conditions like myocardial infarction and atherosclerosis. [13] Furthermore, interactions between key biomolecules, such as the binding of integrin Mac-1 to ICAM-1 and its regulation by glycosylation, illustrate how precise molecular events within these "dense areas" dictate cellular functions, influencing systemic inflammation and hemostatic balance. [7]
Genetic Influence on Lipid and Fatty Acid Metabolism
Genetic variations significantly impact the efficiency of lipid and fatty acid metabolism, a critical aspect of energy balance and cellular function. For instance, single nucleotide polymorphisms (SNPs) near the FADS1 and LIPC genes are associated with modified efficiency of the fatty acid delta-5 desaturase reaction, directly influencing the concentrations of arachidonic acid and other polyunsaturated fatty acids in serum. [15] This enzymatic activity is a key determinant of metabotypes, where genetic variations can strongly affect the balance of direct substrates and products, thereby revealing details on potentially affected metabolic pathways. [15] Analyzing ratios of metabolite concentrations has proven effective in reducing data variation, offering insights into reactions where metabolites are closely linked to enzymatic substrates and products. [15]
Beyond fatty acids, genetic loci influence overall lipid levels and contribute to the risk of coronary heart disease. Variants in genes such as GCKR, the LPL-SLC18A1 region, and the BUD13-APOA cluster (A1/A4/A5/C3) are critical determinants of circulating lipid profiles. [17] For example, common SNPs in HMGCR are associated with LDL-cholesterol levels and modulate alternative splicing of exon 13, directly affecting the regulation of the mevalonate pathway, which is central to cholesterol biosynthesis. [19] Furthermore, genes like ANGPTL3 and ANGPTL4 regulate lipid metabolism, with variations in ANGPTL4 specifically shown to reduce triglycerides and increase HDL. [20]
Regulation of Glucose and Uric Acid Homeostasis
The regulation of glucose homeostasis involves intricate signaling pathways, where genetic variants can predispose individuals to conditions like type 2 diabetes. A common polymorphism in PPAR (Peroxisome Proliferator-Activated Receptor) is associated with a decreased risk of type 2 diabetes, highlighting its role in metabolic signaling and transcription factor regulation. [21] Similarly, large-scale association studies have confirmed that variants in genes encoding the pancreatic beta-cell KATP channel subunits, specifically Kir6.2 (KCNJ11) and SUR1 (ABCC8), are strongly associated with type 2 diabetes. [22] These channels are crucial for glucose-stimulated insulin secretion, and their dysregulation directly impacts cellular signaling cascades critical for maintaining blood glucose levels.
Another key aspect of metabolic regulation involves uric acid homeostasis, which is significantly influenced by genetic factors. The gene SLC2A9, also known as GLUT9, plays a pivotal role, with its variants influencing serum uric acid concentrations and exhibiting pronounced sex-specific effects. [23] GLUT9 is a fructose-transporting protein, and its alternative splicing can alter protein trafficking and function, affecting its role in renal urate transport. [24] Dysregulation of uric acid metabolism is implicated in conditions such as the metabolic syndrome and renal disease, underscoring the broader clinical significance of these genetic and molecular mechanisms. [25]
Molecular Regulatory Mechanisms and Gene Expression
Genetic variants exert their influence through diverse molecular regulatory mechanisms, impacting gene expression and protein function. Beyond direct gene association, changes in intermediate phenotypes, such as metabolic traits, offer a more detailed understanding of affected pathways. [15] One significant mechanism is alternative pre-mRNA splicing, exemplified by common SNPs in HMGCR that affect the splicing of exon 13, thereby modulating the activity of HMG-CoA reductase and cholesterol synthesis. [19] Similarly, alternative splicing of GLUT9 impacts its trafficking and substrate selectivity, influencing uric acid transport. [24]
Transcription factors are central to regulating gene expression, acting as crucial nodes in signaling networks. For instance, the PPAR polymorphism influences the risk of type 2 diabetes by affecting genes involved in glucose and lipid metabolism, demonstrating the power of transcription factor regulation in complex traits. [21] Another example is the regulation by SREBP-2, which defines a potential link between isoprenoid and adenosylcobalamin metabolism, highlighting how specific transcription factors can integrate seemingly disparate metabolic pathways. [26] These regulatory mechanisms, including post-translational modifications, fine-tune protein activity and cellular responses.
Systems-Level Integration and Disease Pathogenesis
Biological systems are characterized by intricate pathway crosstalk and network interactions, where the dysregulation of one pathway can have cascading effects across multiple others. Genome-wide association network analysis (GWANA) is a valuable tool for identifying biological pathways enriched among highly associated genes, particularly in complex traits like lipid metabolism. [17] This systems-level approach moves beyond individual gene associations to reveal the broader network context of genetic variants, providing a more comprehensive view of how genetic polymorphisms collectively influence physiological states. [15] Understanding these network interactions is crucial for comprehending the emergent properties of biological systems, where the collective behavior of interconnected pathways determines the overall phenotype.
Dysregulation within these integrated pathways underlies the pathogenesis of numerous complex diseases, including diabetes, coronary artery disease, and rheumatoid arthritis. [15] While initial genetic association studies often identify variants with small effect sizes on clinical phenotypes, integrating metabolomics data provides a functional readout of the physiological state, offering deeper insights into disease-causing mechanisms. [15] Identifying major genetically determined metabotypes, which are closely related to genetic polymorphisms, offers a step towards personalized health care and nutrition. [15] These insights into pathway dysregulation and the functional consequences of genetic variants are instrumental in identifying potential therapeutic targets and developing individualized medication strategies. [15]
References
[1] O'Donnell CJ. "Genome-wide association study for subclinical atherosclerosis in major arterial territories in the NHLBI's Framingham Heart Study." BMC Med Genet, 2007, PMID: 17903303.
[2] Uda, M., et al. "Genome-wide association study shows BCL11A associated with persistent fetal hemoglobin and amelioration of the phenotype of beta-thalassemia." Proc Natl Acad Sci U S A, vol. 105, no. 5, 2008, pp. 1620-1625.
[3] Sabatti, C., et al. "Genome-wide association analysis of metabolic traits in a birth cohort from a founder population." Nat Genet, vol. 41, no. 1, 2009, pp. 35-46.
[4] Ridker, Paul M., et al. "Loci related to metabolic-syndrome pathways including LEPR,HNF1A, IL6R, and GCKR associate with plasma C-reactive protein: the Women's Genome Health Study." Am J Hum Genet, vol. 82, no. 5, 2008, pp. 1185-92.
[5] Willer CJ. "Newly identified loci that influence lipid concentrations and risk of coronary artery disease." Nat Genet, 2008, PMID: 18193043.
[6] Dehghan, A., et al. "Association of three genetic loci with uric acid concentration and risk of gout: a genome-wide association study." Lancet, vol. 372, no. 9634, 2008, pp. 182-190.
[7] Pare, G., et al. "Novel association of HK1 with glycated hemoglobin in a non-diabetic population: a genome-wide evaluation of 14,618 participants in the Women's Genome Health Study." PLoS Genet, vol. 4, no. 12, 2008, e1000312.
[8] Wallace, C., et al. "Genome-wide association study identifies genes for biomarkers of cardiovascular disease: serum urate and dyslipidemia." Am J Hum Genet, vol. 82, no. 1, 2008, pp. 139-149.
[9] Meigs, J. B., et al. "Genome-wide association with diabetes-related traits in the Framingham Heart Study." BMC Med Genet, vol. 8 Suppl 1, 2007, p. S12.
[10] Yang, Qiong, et al. "Genome-wide association and linkage analyses of hemostatic factors and hematological phenotypes in the Framingham Heart Study." BMC Medical Genetics, vol. 8, no. 1, 2007, p. 69.
[11] Vasan RS. "Genome-wide association of echocardiographic dimensions, brachial artery endothelial function and treadmill exercise responses in the Framingham Heart Study." BMC Med Genet, 2007, PMID: 17903301.
[12] Kathiresan S. "Common variants at 30 loci contribute to polygenic dyslipidemia." Nat Genet, 2008, PMID: 19060906.
[13] Benjamin EJ. "Genome-wide association with select biomarker traits in the Framingham Heart Study." BMC Med Genet, 2007, PMID: 17903293.
[14] Wilk JB. "Framingham Heart Study genome-wide association: results for pulmonary function measures." BMC Med Genet, 2007, PMID: 17903307.
[15] Gieger, C., et al. "Genetics meets metabolomics: a genome-wide association study of metabolite profiles in human serum." PLoS Genet, vol. 4, no. 11, 2008, e1000282.
[16] Cheung, Vivian G., et al. "Mapping Determinants of Human Gene Expression by Regional and Genome-Wide Association." Nature, vol. 437, no. 7063, 2005, pp. 1365–69.
[17] Aulchenko, Y. S., et al. "Loci influencing lipid levels and coronary heart disease risk in 16 European population cohorts." Nat Genet, vol. 41, no. 1, 2009, pp. 47-55.
[18] Eglite, S., et al. "Synthesis and Secretion of Monocyte Chemotactic Protein-1 Stimulated by the High Affinity Receptor for IgE." Journal of Immunology, vol. 170, no. 4, 2003, pp. 2680–87.
[19] Burkhardt, Reiner, et al. "Common SNPs in HMGCR in Micronesians and Whites Associated With LDL-Cholesterol Levels Affect Alternative Splicing of Exon 13." Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 28, no. 12, 2008, pp. 2297-2305.
[20] Koishi, Ryo, et al. "Angptl3 regulates lipid metabolism in mice." Nature Genetics, vol. 30, no. 2, 2002, pp. 151-157.
[21] Altshuler, David, et al. "The common _PPAR_γ2 polymorphism Pro12Ala is associated with decreased risk of type 2 diabetes." Nature Genetics, vol. 26, no. 1, 2000, pp. 76-80.
[22] Gloyn, Anna L., et al. "Large-scale association studies of variants in genes encoding the pancreatic beta-cell KATP channel subunits Kir6.2 (KCNJ11) and SUR1 (ABCC8) confirm that the KCNJ11 E23K variant is associated with type 2 diabetes." Diabetes, vol. 52, no. 2, 2003, pp. 568-572.
[23] Döring, Angela, et al. "SLC2A9 influences uric acid concentrations with pronounced sex-specific effects." Nature Genetics, vol. 40, no. 4, 2008, pp. 430-436.
[24] McArdle, Patrick F., et al. "Association of a Common Nonsynonymous Variant in GLUT9 With Serum Uric Acid Levels in Old Order Amish." Arthritis & Rheumatism, vol. 58, no. 9, 2008, pp. 2894-2900.
[25] Cirillo, Paolo, et al. "Uric Acid, the Metabolic Syndrome, and Renal Disease." Journal of the American Society of Nephrology, vol. 17, no. 12, suppl. 3, 2006, pp. S165-S168.
[26] Murphy, C., et al. "Regulation by SREBP-2 defines a potential link between isoprenoid and adenosylcobalamin metabolism." Biochemical and Biophysical Research Communications, vol. 355, no. 2, 2007, pp. 359-364.